Loading…
CSTL
Castle Biosciences Inc
NASDAQ· Healthcare· Diagnostics & Research· CUSIP 14843C105
$33.19-3.43%Price as of Oct 23, 00:50 UTC · updated once a day, after the close
At a glance
Castle Biosciences Inc (CSTL) is listed on NASDAQ and classified in Diagnostics & Research, part of the Healthcare sector. It is headquartered in Friendswood, United States and has 1,002 employees. The company is worth $1.01B. Revenue was $344.23M in fiscal 2025, up 3.7% from the year before. It reported a net loss of $24.16M. The share price is 25.0% below its 52-week high of $44.28. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Renaissance Technologies, at $8.85M. In that quarter, 3 of them opened or added to the position and 3 reduced it. Over the last 30 days, company insiders sold $1.47M of its stock on the open market and bought none. All of those sales were scheduled in advance under 10b5-1 plans.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $1.01B
- P/E
- —
- Forward P/E
- —
- P/B
- 2.2x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- -$0.62
- ROE
- -4.20%
- Profit margin
- -5.43%
- Revenue growth
- +20.10%
- Beta
- 0.94
- 52-week high
- $44.28
- 52-week low
- $17.72
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -22.7% over 5Y.
today you would have $512.59▼ -48.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 7 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Year-end price | $38.90 | $26.65 | $21.58 | $23.54 | $42.87 | $67.15 | $34.37 | |
| P/E | — | — | 43.0x | — | — | — | — | — |
| P/S | 4.6x | 3.4x | 2.3x | 2.7x | 4.6x | 11.6x | 26.8x | 11.4x |
| P/B |
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
$19.21
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Dividends
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| MNKDMannkind Corp | $3.20 | — | — | 0.00% | — | $1.03B |
| LMRILumexa Imaging Holdings, Inc. | $10.78 | — | 1.7x | 0.00% | — | $1.04B |
| JANXJanux Therapeutics, Inc. | $17.06 | — | 1.1x | 0.00% | -10.70% | $1.04B |
| AVLNAvalyn Pharma Inc. | $23.66 |
About the company
- 1,002
- Friendswood, United States